Association of kynurenine metabolites with cognitive and psychological symptoms in post COVID-19 condition: A case-control study.

Publication date: Nov 01, 2026

Cognitive dysfunction and psychological symptoms, including depression and anxiety, are commonly observed in chronic post COVID condition (PCC). Alterations in the kynurenine pathway have been proposed as a potential underlying mechanism; however, their role in neurocognitive and psychological long-term PCC symptoms remains unclear. This study investigates differences in general cognitive function, verbal memory, psychological distress, and peripheral kynurenine metabolites between individuals with PCC and recovered controls and explores group-specific associations. This study is a subsample of the EPILOC case-control study, assessing PCC (n = 127) and recovered controls (n = 91) ∼75 weeks post-infection. Psychological and neuropsychological measures were consolidated into three components via principal component analysis. Blood samples were analyzed for kynurenine, kynurenic acid, and quinolinic acid. Propensity score matching controlled for confounders. Linear regression models assessed group differences and associations. PCC exhibited worse general cognitive function and higher severity of psychological distress compared to recovered controls (p

Open Access PDF

Concepts Keywords
75weeks Adult
Blood Aged
Models Anxiety
Neuropsychological Anxiety
Pcc Case-Control Studies
Cognitive Dysfunction
Cognitive function
COVID-19
Depression
Depressive symptoms
Female
Humans
Kynurenic Acid
Kynurenic Acid
Kynurenic acid/kynurenine
Kynurenine
Kynurenine
Kynurenine
Male
Middle Aged
Neuropsychological Tests
Post-Acute COVID-19 Syndrome
Psychological Distress
Quinolinic Acid
Quinolinic Acid
Quinolinic acid/kynurenine
SARS-CoV-2
Stress, Psychological

Semantics

Type Source Name
disease MESH COVID-19
disease MESH Cognitive dysfunction
disease MESH anxiety
drug DRUGBANK Factor IX Complex (Human)
disease MESH PCC
disease MESH infection
drug DRUGBANK Kynurenic Acid
drug DRUGBANK Quinolinic Acid
disease MESH Post-Acute COVID-19 Syndrome

Original Article

(Visited 6 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *